What People Call “GLP-3”: Retatrutide and Triple-Agonist Weight Loss Research
Is there really a GLP-3 medication?
“GLP-3” is an informal internet nickname, not an official drug class. The term is often used when people are talking about retatrutide. Retatrutide is more accurately described as an investigational triple hormone receptor agonist because it targets three pathways: GIP, GLP-1 and glucagon.
What is retatrutide?
Retatrutide is being developed by Eli Lilly and is being studied in clinical trials for obesity and other metabolic conditions. As of September 2026, it is investigational and is not FDA-approved or legally available to patients outside authorized clinical trials. Products marketed directly to consumers as retatrutide should not be treated as an approved medication.
Why are triple agonists getting attention?
Researchers are studying whether acting on multiple metabolic hormone pathways can produce meaningful effects on appetite, energy balance, glucose regulation and body weight. Clinical-trial results can be promising without establishing that a medication is approved, appropriate or safe for routine use. Regulatory review remains an essential step.
What can patients do now?
Patients interested in medical weight management can schedule a consultation at SoFlo Medical Center to discuss currently available, medically appropriate options. Our team can explain established treatments, supportive injections, nutrition and follow-up without presenting an investigational drug as an available therapy.
Comments